Press release
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts
About this update from Moonlake Immunotherapeutics
[{"type":"text","content":"MoonLake completes patient randomization ahead of schedule for its Phase 2 trial in active psoriatic arthritis (PsA) and provides calendar of next readouts Randomization target of 200 patients completed ahead of schedule in the ARGO PsA trialTop-line 12-week results of the ARGO trial in PsA for the novel IL-17A and IL-17F inhibiting Nanobody® sonelokimab, are now expected in the first half of November 2023, ahead of the American College of Rheumatology Conference, November 10-15th A Capital Markets Day will be held on September 11th 2023 to discuss the PsA market and share expectations on the ARGO readout and an update on the MIRA trial in Hidradenitis Suppurativa (HS) top-line 24-week data readout, now expected in mid-October 2023, following the recent successful top-line 12-week data readoutThe Company also announces a calendar of upcoming events and data readouts ZUG, Switzerland, July 25, 2023 – MoonLake Immunotherapeutics AG (“MoonLake”; Nasdaq: MLTX), a clinical-stage biotechnology company focused on creating next-level therapies for inflammatory diseases, today announced that it has successfully completed randomization of the target 200 patients, several weeks ahead of schedule, in its global Phase 2 ARGO clinical trial evaluating Nanobody® sonelokimab in active psoriatic arthritis (PsA). MoonLake also announced a Capital Markets Day to be held in New York at NASDAQ, including a virtual webcast format, on September 11th 2023. This session will be used to discuss the PsA market and share expectations on the top-line 12-week ARGO data readout, as well as an update on the MIRA trial in Hidradenitis Suppurativa (HS) 24-week data readout, expected in mid-October 2023, following the successful top-line 12-week data readout. Jorge Santos da Silva, PhD, Founder and Chief Executive Officer at MoonLake, said: “ARGO is MoonLake’s second trial to have achieved faster completion of recruitment and randomization than expected. Reaching this stage well ahead of schedule for active psoriatic arthritis is an encouraging reflection of the interest in our clinical development programs. We are looking forward to all of the upcoming key MoonLake readouts and events and are excited about updating investors with our progress in due course.” The ARGO trial in PsAThe ARGO trial (NCT05640245) commenced patient screening in December 2022 with the a...